🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesMy blood pressure normalization journey — July 2024

My blood pressure normalization journey — July 2024

JessicaH_TX Sat, Aug 16, 2025 at 1:11 PM 25 replies 1,700 viewsPage 1 of 5
This thread is more than 9 months old. Information may be outdated. Consider searching for more recent discussions.
JessicaH_TX
Senior Member
4,123
13,456
Dec 2023
Houston, TX
Aug 16, 2025 at 1:11 PM#1

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Relative versus absolute is the distinction that gets lost: a 20% relative reduction on a high baseline risk is a large absolute benefit, and the same relative figure on a low baseline risk is a small one.

The question I want answered is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

I would rather have one careful answer than five confident ones.

5 8wendy_avl, jason_paloalto, Dr.LeslieOBGYN and 2 others
Reply Quote Save Share Report
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Aug 16, 2025 at 2:03 PM#2
JessicaH_TX said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.

References:
[1] Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844.
6 9kim_atl_prep, sarah_TO, wendy_avl and 3 others
Reply Quote Save Share Report
jason_paloalto
Member
212
890
Nov 2024
Palo Alto, CA
Aug 16, 2025 at 2:55 PM#3
Dr.SleepRoch said:
SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk.
Dr.SleepRoch said:
...we don't know the long-term effects of cardiovascular risk...

This is a fair point, and I think intellectual honesty requires acknowledging it. GLP-1 agonists in their current form have ~8-10 years of human exposure data. That's not nothing, but it's not 30+ years either.

However: the risk-benefit calculation should also consider the KNOWN long-term effects of untreated obesity — diabetes, cardiovascular disease, cancer, joint destruction, reduced lifespan by 5-10 years.

Uncertainty about GLP-1 long-term safety vs certainty about obesity consequences. The calculus seems clear to me, but reasonable people can disagree.

7 10mona_PHX, andrew_nyc, Dr.EndoEP and 4 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
DeniseRN_TPA
Member
345
1,567
Aug 2024
Tampa, FL
Aug 16, 2025 at 3:47 PM#4
JessicaH_TX said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Adding a me-too, because a thread of one person's experience is not much use. The detail I would add is minor and it is already implied above.

8 11LindaRN_retired, tommy_boulder, hyun_seoul and 5 others
Reply Quote Save Share Report
roxy_nash
Member
178
890
Dec 2024
Nashville, TN
Aug 16, 2025 at 8:44 PM#5

Adding the clinical framing, because it changes how the question reads.

Senior perspective on cardiovascular risk: I'm 62 years old and started this journey skeptically. My cardiologist recommended it after years of failed interventions.

14 months later: down 55 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

9 12kim_atl_prep, sarah_TO, wendy_avl and 6 others
Reply Quote Save Share Report
1235

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register